Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Sodium-Glucose Transporter 2 Inhibitors”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT02964247
What this trial is testing

LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.

Who this might be right for
DiabetesDiabetes Mellitus, Type 2
Novo Nordisk A/S 303
Post-approval studies (Phase 4)Study completedNCT03267576
What this trial is testing

An Efficacy Study of Canagliflozin or Sitagliptin to Determine Glucose Variability in Mexican Participants With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin

Who this might be right for
Diabetes Mellitus, Type 2
Janssen Research & Development, LLC 64
Large-scale testing (Phase 3)Ended earlyNCT05036317
What this trial is testing

Empagliflozin for the Treatment of Postprandial Hypoglycemia

Who this might be right for
Postprandial Hypoglycemia
University Hospital, Basel, Switzerland 40
Post-approval studies (Phase 4)UnknownNCT04340908
What this trial is testing

Effects of SGLT2 Inhibitor on Type 2 Diabetic Patients Undergoing Cardiac Surgery

Who this might be right for
Diabetes Mellitus, Type 2Cardiac Surgery
Hongchang Guo 500
Post-approval studies (Phase 4)Study completedNCT06374043
What this trial is testing

Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin.

Who this might be right for
Diabetes Mellitus, Type 2Diabetes Mellitus Type 2 With ProteinuriaDiabetes Mellitus+7 more
University Medical Center Groningen 20
Testing effectiveness (Phase 2)UnknownNCT06147271
What this trial is testing

Impact of SGLT2 Inhibitors in Heart Transplant Recipients

Who this might be right for
Transplant; Failure, HeartCardiac Allograft VasculopathyRejection Heart Transplant
Universidade Federal do Ceara 80
Large-scale testing (Phase 3)Active Not RecruitingNCT06149793
What this trial is testing

SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes

Who this might be right for
Cystic Fibrosis-related DiabetesCystic Fibrosis
University of Minnesota 8
Large-scale testing (Phase 3)WithdrawnNCT03173963
What this trial is testing

Empaglifozin in Early Diabetic Kidney Disease

Who this might be right for
Diabetic Kidney DiseaseDiabetes Mellitus Type 2
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Early research (Phase 1)Looking for participantsNCT07703163
What this trial is testing

Safety and Efficacy of Canagliflozin in Patients With Locally Advanced or Advanced Solid Cancer

Who this might be right for
Solid TumorSGLT 2 Inhibitors
West China Hospital 15
Post-approval studies (Phase 4)Study completedNCT05057819
What this trial is testing

Investigating the Impact of the SGLT2 Inhibitor Empagliflozin on Postprandial Hypoglycaemia After Gastric Bypass

Who this might be right for
Dumping SyndromeHypoglycemia, Reactive
Insel Gruppe AG, University Hospital Bern 22
Not applicableUnknownNCT06201000
What this trial is testing

Effect of Genetic Polymorphisms on the Clinical Response to SGLT2 Inhibitors in Heart Failure Patients

Who this might be right for
Genetic PolymorphismsHeart Failure
October 6 University 282
Not applicableLooking for participantsNCT06271200
What this trial is testing

Strategic Lifestyle Intervention for Metabolic Syndrome (SLIM-MET)

Who this might be right for
Metabolic Syndrome
National Health Research Institutes, Taiwan 200
Post-approval studies (Phase 4)Study completedNCT02653482
What this trial is testing

Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure

Who this might be right for
Chronic Heart Failure With Reduced Systolic Function
Saint Luke's Health System 263
Post-approval studies (Phase 4)Ended earlyNCT04071626
What this trial is testing

Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure

Who this might be right for
Heart Failure, DiastolicDiabetes Mellitus, Type 2
University Hospitals Cleveland Medical Center 9
Not applicableStudy completedNCT02479399
What this trial is testing

Specified Drug Use Results Survey of Ipragliflozin Treatment in type2 Diabetes Patients

Who this might be right for
Type 2 Diabetes
Astellas Pharma Inc 11,412
Post-approval studies (Phase 4)UnknownNCT04127084
What this trial is testing

Effects of SGLT2 Inhibition Treatment on Different Levels of Albuminuria in Patients With Type 2 Diabetes

Who this might be right for
Type 2 DiabetesDiabetic Nephropathy
Zhongshan Hospital Xiamen University 70
Testing effectiveness (Phase 2)Looking for participantsNCT06435156
What this trial is testing

Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes

Who this might be right for
Type 1 DiabetesHeart Failure
University of Dundee 320
Not applicableStudy completedNCT06903754
What this trial is testing

ISGLT2 in Patients Without DM With Acute MI

Who this might be right for
Acute Coronary SyndromesHeart Failure
Mohammed VI University Hospital 450
Not applicableStudy completedNCT05335629
What this trial is testing

Evaluation of the Effect of SGLT-2 Inhibitors on Cardiac Remodeling in Post Myocardial Infarction Patients

Who this might be right for
Myocardial InfarctionDiabetes Mellitus, Type 2Myocardial Remodeling, Ventricular
Ain Shams University 54
Large-scale testing (Phase 3)Looking for participantsNCT06024746
What this trial is testing

Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)

Who this might be right for
Heart Failure
Colorado Prevention Center 1,500
Next Page